KLDO News and Press, Kaleido Biosciences Inc. From 08/05/20

LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Michael Bonney, Executive Chair, wil...

Kaleido Biosciences (NASDAQ: KLDO ) : Q2 GAAP EPS of -$0.59 misses by $0.03 . More news on: Kaleido Biosciences, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 -   LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a ...

In partnership with Boston's Mass General Hospital, Kaleido Biosciences (NASDAQ: KLDO ) initiates a non-IND clinical study evaluating Microbiome Metabolic Therapy (MMT) candidate KB109 on top of supportive self-care (SSC) in ~50 outpatients with mild-to-moderate COVID-19. More news on:...

- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven appro...

CAMBRIDGE, Mass. , July 7, 2020 /PRNewswire/ -- Flagship Pioneering today announced the unveiling of Tessera Therapeutics, Inc. a new company with the mission of curing disease by writing in the code of life. Tessera is pioneering Gene Writing™, a new biotechnology that writes ther...

Kaleido Biosciences (NASDAQ: KLDO ) announced  Alison Lawton to step down as President and CEO to attend to a family health matter. More news on: Kaleido Biosciences, Inc., Read more ...

- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter - The Board of Directors has established an Office of the CEO to manage the company through the transition, with Mike Bonney, Executive Chair, to lead the office and Alison Lawt...

LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that in light of the COVID-19 pandemic, i...

LEXINGTON, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Alison Lawton, President and Chief E...